Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3

Human Molecular Genetics

Volumn 15, Issue 1, 2006, Pages 129-142

  Hernández Deviez, Delia J ^a   Martin, Sally ^a   Laval, Steven H ^b   Lo, Harriet P ^c   Cooper, Sandra T ^c   North, Kathryn N ^c   Bushby, Kate ^b   Parton, Robert G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSTITUTE OF HUMAN GENETICS   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CAVEOLIN 3; DYSFERLIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DYSTROPHY; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC LINKAGE; GENETIC TRANSFECTION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

ANIMALS; CAVEOLIN 3; CELL MEMBRANE; CELLS, CULTURED; FEMALE; GOLGI APPARATUS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MICE; MICROSCOPY, FLUORESCENCE; MICROSCOPY, IMMUNOELECTRON; MUSCLE FIBERS; MUTATION; PROTEIN TRANSPORT;

ANIMALIA;

EID: 29644441031     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddi434     Document Type: Article

References (65)

1. Durbeej, M. and Campbell, K.P. (2002) Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr. Opin. Genet. Dev., 12, 349-361.
2. Bashir, R., Britton, S., Strachan, T., Keers, S., Vafiadaki, E., Lako, M., Richard, I., Marchand, S., Bourg, N., Argov, Z. et al. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet., 20, 37-42.
3. Yasunaga, S., Grati, M., Cohen-Salmon, M., El-Amraoui, A., Mustapha, M., Salem, N., El-Zir, E., Loiselet, J. and Petit, C. (1999) A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat. Genet., 21, 363-369.
4. Britton, S., Freeman, T., Vafiadaki, E., Keers, S., Harrison, R., Bushby, K. and Bashir, R. (2000) The third human FER-1-like protein is highly similar to dysferlin. Genomics, 68, 313-321.
5. Davis, D.B., Delmonte, A.J., Ly, C.T. and McNally, E.M. (2000) Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum. Mol. Genet., 9, 217-226.
6. Liu, J., Aoki, M., Illa, I., Wu, C., Fardeau, M., Angelini, C., Serrano, C., Urtizberea, J.A., Hentati, F., Hamida, M.B. et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet., 20, 31-36.
7. Matsuda, C., Aoki, M., Hayashi, Y.K., Ho, M.F., Arahata, K. and Brown, R.H., Jr (1999) Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology, 53, 1119-1122.
8. Illa, I., Serrano-Munuera, C., Gallardo, E., Lasa, A., Rojas-Garcia, R., Palmer, J., Gallano, P., Baiget, M., Matsuda, C. and Brown, R.H. (2001) Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol., 49, 130-134.
9. Bansal, D. and Campbell, K.P. (2004) Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol., 14, 206-213.
10. Montesano, R., Roth, J., Robert, A. and Orci, L. (1982) Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature, 296, 651-653.
11. Parton, R.G. (1994) Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem., 42, 155-166.
12. Scheiffele, P., Verkade, P., Fra, A.M., Virta, H., Simons, K. and Ikonen, E. (1998) Caveolin-1 and -2 in the exocytic pathway of MDCK cells. J. Cell Biol., 140, 795-806.
13. Verkade, P., Harder, T., Lafont, F. and Simons, K. (2000) Induction of caveolae in the apical plasma membrane of Madin-Darby canine kidney cells. J. Cell Biol., 148, 727-739.
14. Wyse, B.D., Prior, I.A., Qian, H., Morrow, I.C., Nixon, S., Muncke, C., Kurzchalia, T.V., Thomas, W.G., Parton, R.G. and Hancock, J.F. (2003) Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J. Biol. Chem., 278, 23738-23746.
15. Roy, S., Luetterforst, R., Harding, A., Apolloni, A., Etheridge, M., Stang, E., Rolls, B., Hancock, J.F. and Parton, R.G. (1999) Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol., 1, 98-105.
16. Kurzchalia, T.V. and Parton, R.G. (1999) Membrane microdomains and caveolae. Curr. Opin. Cell Biol., 11, 424-431.
17. Razani, B., Schlegel, A. and Lisanti, M.P. (2000) Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy.J Cell Sci., 113, 2103-2109.
18. Scherer, P.E., Lewis, R.Y., Volonte, D., Engelman, J.A., Galbiati, F., Couet, J., Kohtz, D.S., van Donselaar, E., Peters, P. and Lisanti, M.P. (1997) Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J. Biol. Chem., 272, 29337-29346.
19. Way, M. and Parton, R.G. (1995) M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett., 376, 108-112.
20. Segal, S.S., Brett, S.E. and Sessa, W.C. (1999) Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am. J. Physiol., 277, H1167-H1177.
21. Song, K.S., Scherer, P.E., Tang, Z., Okamoto, T., Li, S., Chafel, M., Chu, C., Kohtz, D.S. and Lisanti, M.P. (1996) Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J. Biol. Chem., 271, 15160-15165.
22. Doyle, D.D., Upshaw-Earley, J., Bell, E. and Palfrey, H.C. (2003) Expression of caveolin-3 in rat aortic vascular smooth muscle cells is determined by developmental state. Biochem. Biophys. Res. Commun., 304, 22-25.
23. McNally, E.M., de Sa Moreira, E., Duggan, D.J., Bonnemann, C.G., Lisanti, M.P., Lidov, H.G., Vainzof, M., Passos-Bueno, M.R., Hoffman, E.P., Zatz, M. et al. (1998) Caveolin-3 in muscular dystrophy. Hum. Mol. Genet., 7, 871-877.
24. Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E., Mazzocco, M., Egeo, A., Donati, M.A. et al. (1998) Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet., 18, 365-368.
25. Carbone, I., Bruno, C., Sotgia, F., Bado, M., Broda, P., Masetti, E., Panella, A., Zara, F., Bricarelli, F.D., Cordone, G. et al. (2000) Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology, 54, 1373-1376.
26. Betz, R.C., Schoser, B.G., Kasper, D., Ricker, K., Ramirez, A., Stein, V., Torbergsen, T., Lee, Y.A., Nothen, M.M., Wienker, T.F. et al. (2001) Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat. Genet., 28, 218-219.
27. Vorgerd, M., Ricker, K., Ziemssen, F., Kress, W., Goebel, H.H., Nix, W.A., Kubisch, C., Schoser, B.G. and Mortier, W. (2001) A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology, 57, 2273-2277.
28. Merlini, L., Carbone, I., Capanni, C., Sabatelli, P., Tortorelli, S., Sotgia, F., Lisanti, M.P., Bruno, C. and Minetti, C. (2002) Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J. Neurol. Neurosurg. Psychiat., 73, 65-67.
29. Tateyama, M., Aoki, M., Nishino, I., Hayashi, Y.K., Sekiguchi, S., Shiga, Y., Takahashi, T., Onodera, Y., Haginoya, K., Kobayashi, K. et al. (2002) Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. Neurology, 58, 323-325.
30. Figarella-Branger, D., Pouget, J., Bernard, R., Krahn, M., Fernandez, C., Levy, N. and Pellissier, J.F. (2003) Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene. Neurology, 61, 562-564.
31. Fischer, D., Schroers, A., Blumcke, I., Urbach, H., Zerres, K., Mortier, W., Vorgerd, M. and Schroder, R. (2003) Consequences of a novel caveolin-3 mutation in a large German family. Ann. Neurol., 53, 233-241.
32. Kubisch, C., Schoser, B.G., von During, M., Betz, R.C., Goebel, H.H., Zahn, S., Ehrbrecht, A., Aasly, J., Schroers, A., Popovic, N. et al. (2003) Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann. Neurol., 53, 512-520.
33. Parton, R.G., Way, M., Zorzi, N. and Stang, E. (1997) Caveolin-3 associates with developing T-tubules during muscle differentiation.J. Cell Biol., 136, 137-154.
34. Matsuda, C., Hayashi, Y.K., Ogawa, M., Aoki, M., Murayama, K., Nishino, I., Nonaka, I., Arahata, K. and Brown, R.H., Jr (2001) The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum. Mol. Genet., 10, 1761-1766.
35. Capanni, C., Sabatelli, P., Mattioli, E., Ognibene, A., Columbaro, M., Lattanzi, G., Merlini, L., Minetti, C., Maraldi, N.M. and Squarzoni, S. (2003) Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition. Exp. Mol. Med., 35, 538-544.
36. Yabe, I., Kawashima, A., Kikuchi, S., Higashi, T., Fukazawa, T., Hamada, T., Sasaki, H. and Tashiro, K. (2003) Caveolin-3 gene mutation in Japanese with rippling muscle disease. Acta Neurol. Scand., 108, 47-51.
37. Sugie, K., Murayama, K., Noguchi, S., Murakami, N., Mochizuki, M., Hayashi, Y.K., Nonaka, I. and Nishino, I. (2004) Two novel CAV3 gene mutations in Japanese families. Neuromuscul. Disord., 14, 810-814.
38. Carozzi, A.J., Roy, S., Morrow, I.C., Pol, A., Wyse, B., Clyde-Smith, J., Prior, I.A., Nixon, S.J., Hancock, J.F. and Parton, R.G. (2002) Inhibition of lipid raft-dependent signaling by a dystrophy-associated mutant of caveolin-3. J. Biol. Chem., 277, 17944-17949.
39. Galbiati, F., Volonte, D., Minetti, C., Chu, J.B. and Lisanti, M.P. (1999) Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J. Biol. Chem., 274, 25632-25641.
40. Ren, X., Ostermeyer, A.G., Ramcharan, L.T., Zeng, Y., Lublin, D.M. and Brown, D.A. (2004) Conformational defects slow Golgi exit, block oligomerization, and reduce raft affinity of caveolin-1 mutant proteins. Mol. Biol. Cell, 15, 4556-4567.
41. Galbiati, F., Razani, B. and Lisanti, M.P. (2001) Caveolae and caveolin-3 in muscular dystrophy. Trends Mol. Med., 7, 435-441.
42. Roberts HL, L.H., Day B, North KN (2005) Rippling muscle disease due to mutation in caveolin-3. J. Clin. Neurosci. (in press).
43. Anderson, L.V., Davison, K., Moss, J.A., Young, C., Cullen, M.J., Walsh, J., Johnson, M.A., Bashir, R., Britton, S., Keers, S. et al. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum. Mol. Genet., 8, 855-861.
44. Piccolo, F., Moore, S.A., Ford, G.C. and Campbell, K.P. (2000) Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb - girdle muscular dystrophies. Ann. Neurol., 48, 902-912.
45. Bansal, D., Miyake, K., Vogel, S.S., Groh, S., Chen, C.C., Williamson, R., McNeil, P.L. and Campbell, K.P. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature, 423, 168-172.
46. Rahkila, P., Takala, T.E., Parton, R.G. and Metsikko, K. (2001) Protein targeting to the plasma membrane of adult skeletal muscle fiber: An organized mosaic of functional domains. Exp. Cell Res., 267, 61-72.
47. Ralston, E. and Ploug, T. (1999) Caveolin-3 is associated with the T-tubules of mature skeletal muscle fibers. Exp. Cell Res., 246, 510-515.
48. Davis, D.B., Doherty, K.R., Delmonte, A.J. and McNally, E.M. (2002) Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J. Biol. Chem., 277, 22883-22888.
49. Tang, Z., Scherer, P.E., Okamoto, T., Song, K., Chu, C., Kohtz, D.S., Nishimoto, I., Lodish, H.F. and Lisanti, M.P. (1996) Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem., 271, 2255-2261.
50. Lee, H., Park, D.S., Razani, B., Russell, R.G., Pestell, R.G. and Lisanti, M.P. (2002) Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1(-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol., 161, 1357-1369.
51. Hayashi, K., Matsuda, S., Machida, K., Yamamoto, T., Fukuda, Y., Nimura, Y., Hayakawa, T. and Hamaguchi, M. (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res., 61, 2361-2364.
52. Sotgia, F., Razani, B., Bonuccelli, G., Schubert, W., Battista, M., Lee, H., Capozza, F., Schubert, A.L., Minetti, C., Buckley, J.T. et al. (2002) Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells. Mol. Cell. Biol., 22, 3905-3926.
53. Herrmann, R., Straub, V., Blank, M., Kutzick, C., Franke, N., Jacob, E.N., Lenard, H.G., Kroger, S. and Voit, T. (2000) Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum. Mol. Genet., 9, 2335-2340.
54. Arbuzova, A., Wang, L., Wang, J., Hangyas-Mihalyne, G., Murray, D., Honig, B. and McLaughlin, S. (2000) Membrane binding of peptides containing both basic and aromatic residues. Experimental studies with peptides corresponding to the scaffolding region of caveolin and the effector region of MARCKS. Biochemistry, 39, 10330-10339.
55. Pol, A., Martin, S., Fernandez, M.A., Ingelmo-Torres, M., Ferguson, C., Enrich, C. and Parton, R.G. (2005) Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies. Mol. Biol. Cell, 16, 2091-2105.
56. Tagawa, A., Mezzacasa, A., Hayer, A., Longatti, A., Pelkmans, L. and Helenius, A. (2005) Assembly and trafficking of caveolar domains in the cell: Caveolae as stable, cargo-triggered, vesicular transporters. J. Cell Biol., 170, 769-779.
57. Fra, A.M., Williamson, E., Simons, K. and Parton, R.G. (1995) De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc. Natl Acad. Sci. USA, 92, 8655-8659.
58. Luetterforst, R., Stang, E., Zorzi, N., Carozzi, A., Way, M. and Parton, R.G. (1999) Molecular characterization of caveolin association with the Golgi complex: Identification of a cis-Golgi targeting domain in the caveolin molecule. J. Cell Biol., 145, 1443-1459.
59. Bekoff, A. and Betz, W. (1977) Properties of isolated adult rat muscle fibres maintained in tissue culture. J. Physiol., 271, 537-547.
60. Rahkila, P., Alakangas, A., Vaananen, K. and Metsikko, K. (1996) Transport pathway, maturation, and targeting of the vesicular stomatitis virus glycoprotein in skeletal muscle fibers. J. Cell Sci., 109, 1585-1596.
61. Razani, B., Engelman, J.A., Wang, X.B., Schubert, W., Zhang, X.L., Marks, C.B., Macaluso, F., Russell, R.G., Li, M., Pestell, R.G. et al. (2001) Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem., 276, 38121-38138.
62. Carozzi, A.J., Ikonen, E., Lindsay, M.R. and Parton, R.G. (2000) Role of cholesterol in developing T-tubules: Analogous mechanisms for T-tubule and caveolae biogenesis. Traffic, 1, 326-341.
63. Richards, A.A., Stang, E., Pepperkok, R. and Parton, R.G. (2002) Inhibitors of COP-mediated transport and cholera toxin action inhibit simian virus 40 infection. Mol. Biol. Cell, 13, 1750-1764.
64. Martin, S., Millar, C.A., Lyttle, C.T., Meerloo, T., Marsh, B.J., Gould, G.W. and James, D.E. (2000) Effects of insulin on intracellular GLUT4 vesicles in adipocytes: Evidence for a secretory mode of regulation. J. Cell Sci., 113, 3427-3438.
65. Cooper, S.T., Lo, H.P. and North, K.N. (2003) Single section western blot: Improving the molecular diagnosis of the muscular dystrophies. Neurology, 61, 93-97.